CN101711758A - Application of apigenin in preparing medicament for preventing and treating diseases caused by ischemic injuries of humans - Google Patents
Application of apigenin in preparing medicament for preventing and treating diseases caused by ischemic injuries of humans Download PDFInfo
- Publication number
- CN101711758A CN101711758A CN200910084958A CN200910084958A CN101711758A CN 101711758 A CN101711758 A CN 101711758A CN 200910084958 A CN200910084958 A CN 200910084958A CN 200910084958 A CN200910084958 A CN 200910084958A CN 101711758 A CN101711758 A CN 101711758A
- Authority
- CN
- China
- Prior art keywords
- ischemia
- disease
- apigenin
- cell
- application according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 235000008714 apigenin Nutrition 0.000 title claims abstract description 35
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 229940117893 apigenin Drugs 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 13
- 201000010099 disease Diseases 0.000 title claims abstract description 11
- 208000037906 ischaemic injury Diseases 0.000 title claims abstract description 4
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 10
- 208000028867 ischemia Diseases 0.000 claims abstract description 10
- 230000006378 damage Effects 0.000 claims abstract description 7
- 206010022680 Intestinal ischaemia Diseases 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 8
- 201000006474 Brain Ischemia Diseases 0.000 claims description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 206010038470 Renal infarct Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 206010028320 muscle necrosis Diseases 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 abstract description 3
- 208000030016 Avascular necrosis Diseases 0.000 abstract 1
- 206010031264 Osteonecrosis Diseases 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 41
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 21
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 19
- 230000017074 necrotic cell death Effects 0.000 description 19
- 206010028851 Necrosis Diseases 0.000 description 18
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 description 16
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 description 16
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 13
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 11
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 11
- 230000034994 death Effects 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000000302 ischemic effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 7
- TXUWMXQFNYDOEZ-UHFFFAOYSA-N 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone Chemical compound O=C1N(C)C(=S)NC1CC1=CNC2=CC=CC=C12 TXUWMXQFNYDOEZ-UHFFFAOYSA-N 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 101150099575 CDC37 gene Proteins 0.000 description 6
- 108010006519 Molecular Chaperones Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229960000715 nimodipine Drugs 0.000 description 6
- 102000005431 Molecular Chaperones Human genes 0.000 description 5
- 101150071716 PCSK1 gene Proteins 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 229940109262 curcumin Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102000009058 Death Domain Receptors Human genes 0.000 description 3
- 108010049207 Death Domain Receptors Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000023589 ischemic disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 102000043139 CK2 family Human genes 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 241000218641 Pinaceae Species 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- -1 Polyphenols flavone compound Chemical class 0.000 description 1
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 101150001535 SRC gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004691 chief cell of stomach Anatomy 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000021597 necroptosis Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to application of apigenin in preparing a medicament for preventing and treating diseases caused by ischemic injuries of humans, wherein the diseases comprise acute myocardial infarctions, cerebral infarctions, intestinal ischemia, avascular necrosis of limbs and necrocytosis and function damages caused by ischemia of organs of livers, kidneys, and the like.
Description
One, technical field
The present invention relates to of the application of natural drug apigenin as the preventive or the therapeutic agent of ischemia injury disease.
Two, background technology
When the organ or tissue of body narrow or inaccessible when not having sufficient side Zhi Xunhuan or side Zhi Xunhuan in time not to set up because of lumen of artery, cytopathy and necrosis can take place owing to anoxia, nutrient substance input pause and metabolite gathering etc. change in ischemic tissue, the ischemic necrosis of this local organization is called infarction again.Take care, during vitals generation infarction such as brain, will obviously influence the heart, brain function, serious threat people's life not only also will obviously reduce survival patient's work capacity and quality of life.
Cell stress with the damage situation under, death can take place, its type comprises apoptosis and necrosis.People think always for a long time, and apoptosis belongs to programmed cell death, are the active death process that is subjected to the several genes network regulation, and are downright bad then be the passive death process that can not regulate and control.Yet progress in recent years shows, the necrosis of cell also can be to mediate by the activation of multiple signal transduction path, regulated and control by gene, epigenetic and medicine, and play an important role at fetal development and maintaining in the homeostatic process of adult tissue as apoptotic process, therefore also be classified as programmed cell death
[1-4]Discover that the RIP1 kinases is played an important role in the cell in the process of the procedural necrocytosis of mediation
[5], adopt the kinase whose activity of micromolecular inhibitor blocking-up RIP1 can effectively suppress the generation of procedural necrosis
[6]Because proteic stability of RIP1 and kinase activity need the molecular chaperone function of heat shock protein 90 (Hsp90), therefore the molecular chaperone function that suppresses Hsp90 can cause the degraded of RIP1 kinases, thereby blocks the generation of procedural necrosis by reducing the proteic expression of RIP1
[7,8]The RIP1 kinases micromolecular inhibitor Necrostatins that has been found that can be by the kinase activity of blocking-up RIP1; and then the protection of the approach by the non-dependence of radical damage cell avoids the necrosis that ischemia causes, and all shows tangible cytoprotection in the cerebral ischemic model of laboratory animal and myocardial infarction and ischemia model
[9,10]Not only can reduce cell death quantity owing to suppress the generation of the procedural necrocytosis of ischemia mediation, more can alleviate the follow-up inflammatory reaction that produces by the necrocytosis mediation, thereby will provide new therapeutic strategy for the treatment ischemic diseases by the generation of targeting inhibition RIP1 albumen (suppress its kinase activity or reduce its protein expression) blocking-up programmed cell necrosis.
List of references
1.Degterev?A?and?Yuan?J.Expansion?and?evolution?of?cell?death?programmes?Nat?RevMol?Cell?Biol.2008?May；9(5)：378-90
2.Kroemer?G，et?al.Classification?of?cell?death：recommendations?of?theNomenclature?Committee?on?Cell?Death?2009.Cell?Death?Differ.2009?Jan；16(1)：3-11
3.Golstein?P，Kroemer?G.Cell?death?by?necrosis：towards?a?molecular?definition.Trends?Biochem?Sci.2007Jan；32(1)：37-43
4.Galluzzi?L?and?Kroemer?G.Necroptosis：a?specialized?pathway?of?programmednecrosis.Cell.2008?Dec?26；135(7)：1161-3
5.Festjens?N，et?al.RIP1，a?kinase?on?the?crossroads?of?a?cell’s?decision?to?liveor?die.Cell?Death?Differ.2007；14：400-410
6.Degterev?A，et?al.Identification?of?RIP1?kinase?as?a?specific?cellular?targetof?necrostatins.Nat?Chem?Biol.2008?May；4(5)：313-21
7.Holler?N，et?al.Fas?triggers?an?alternative，caspase-8-independent?cell?deathpathway?using?the?kinase?RIP?as?effector?molecule.Nat?Immunol?2000；1(6)：489-495
8.Horita?H，et?al.Acute?myeloid?leukemia-targeted?toxin?activates?both?apoptoticand?necroptotic?death?mechani?sms.PLoS?ONE.2008；3(12)：e3909
9.cDegterev?A，et?al.Chemical?inhibitor?of?nonapoptotic?cell?death?with?therapeuticpotential?for?ischemic?brain?injury.Nat?Chem?Biol.2005Jul；1(2)：112-9
10.Christopher?CTS，et?al.Necrostatin：A?Potentially?Novel?Cardioprotective?Agent？Cardiovasc?Drugs?Ther(2007)21：227-233
Three, summary of the invention
The present invention relates to the new purposes of apigenin on preparation prevention and treatment ischemic diseases, its objective is that providing a kind of brings into play the caused biological organs damage of antagonism ischemia and alleviate its handicapped prevention and medicine by the blocking-up programmed cell is downright bad.
Apigenin (Apigenin, 4 ', 5,7-Trihydroxyflavone, 5,7-dihydroxy-2-(4-hydroxyphenyl)-4h-1-benzopyran-4-on, 4,5, the 7-trihydroxyflavone) is main bioactive ingredients in the Herba Apii graveolentis, extensively be present in multiple fruit, vegetable, beans and Folium Camelliae sinensis, goatweed HERBA VERONICAE DILATATAE, Polygonaceae Rhizoma Polygoni Cuspidati, Liliaceae hair leaf Rhizoma et radix veratri (Radix Rhizoma Veratri) and the pinaceae plant, belong to the Polyphenols flavone compound, have the various biological activity.Have now and studies show that it has the effects such as carcinogenic activity, antiviral, antiinflammatory, antioxidation and cell death inducing that suppress carcinogen, therefore be used to experimental treatments such as antitumor, though being arranged early stage, indivedual researchs notice that apigenin can alleviate the liver dysfunction phenomenon that nerve injury regulating liver-QI ischemic reperfusion that the perfusion of cerebral ischemia-again causes causes, but because of not knowing its mechanism of action, so can't clear and definite apigenin can be widely used in the blocking treatment of ischemic necrosis.
We find under study for action, under appropriate drug concentration, apigenin is in the cultured cell in vitro system, thereby can be by suppressing the phosphorylation [Fig. 1] that intracellular CK2 kinases reduces auxiliary chaperone cdc37 important in the Hsp90 complex, because the phosphorylation of cdc37 is vital for the molecular chaperone function that maintains Hsp90, the phosphorylation that reduces cdc37 can cause the molecular chaperone function of Hsp90 to be suppressed, the substrate protein molecule that mediates multiple Hsp90 is degraded, comprising necrosis has the RIP1 kinase protein of important mediation for programmed cell, compare with other natural drugs with Hsp90 inhibit feature, tripterine (Cel) can obviously reduce the expression of RIP1, but induce PARP albumen to shear simultaneously, apoptosis appears in cell, and the prompting cytotoxicity is stronger.Curcumin (Cur) then shows to have the effect that reduces the RIP1 protein expression, has only apigenin cell death inducing (Fig. 2) not when reducing RIP1 and expressing.Continue we in the experimental system of external programmed cell necrosis by death receptor mediation, detected the influence of apigenin and tripterine for the programmed cell necrosis of blocking-up death receptor mediation; the result shows that tripterine has stronger cytotoxicity really; the apigenin pretreatment then can obviously strengthen the toleration [Fig. 3] of L929 cell to the necrosis of tumor necrosis factor mediated cell; confirm that apigenin can be by the effect of powerful reduction RIP1 kinase protein level; realize the protective effect of the procedural necrosis of its pair cell, and its action effect and known necrocytosis protective agent Necrostatin-1 (Nec-1) suitable [Fig. 3].Protective effect cerebral ischemia in the rat body-reperfusion injury model of apigenin pair cell antagonism necrosis is also further confirmed [table 1].
Four, description of drawings
Fig. 1. apigenin (Api) is handled prostate cancer cell line LNCaP and PC-3 cell by the time of selecting, cracking behind the collecting cell, adopt the capable co-immunoprecipitation of anti-Cdc37 antibody (IP) experiment, precipitated product carries out the protein blot detection with anti-phosphorylation serine, Cdc37, Hsp90 and androgen (AR) antibody respectively through SDS-PAGE and after changeing film, is reference with full cell pyrolysis liquid (WCL).But the result shows apigenin time-dependent ground and reduces the phosphorylation of Cdc37, and Cdc37 and Hsp90 and substrate A R and Cdk4 combine the molecular chaperone function of inhibition Hsp90.
Fig. 2. after apigenin is handled prostate cancer cell line LNCaP and PC-3 cell, the collecting cell cracking, the protein blot method detects the change of each protein expression.But the result induces with showing the apigenin time dependence and comprises multiple Hsp90 substrate protein degraded such as RIP-1, Src, XIAP, Cdk4, Survivin.
Fig. 3. the protein blot method compares natural drug tripterine (Cel), curcumin (Cur) and apigenin (Api) to L929 cell RIP1 protein stability and apoptotic influence, the result shows that tripterine can obviously reduce the proteic expression of RIP1, but cause the shearing of PARP albumen simultaneously, cell death inducing.All less than influence, only apigenin can effectively reduce the proteic level of RIP1 to curcumin to RIP1 and PARP albumen, does not shear the protein induced apoptosis of PARP simultaneously.
Fig. 4. adopt the viable count method to detect tumor necrosis factor TNF-alpha and induce the L929 necrocytosis; compare Nec-1, apigenin and tripterine pretreatment influence simultaneously to the necrosis of TNF-α inducing cell; the result shows that tripterine self cytotoxicity is stronger; and apigenin has the good cell protective effect, and its effect is suitable with known necrocytosis protective agent Nec-1.
Five, the specific embodiment
Only the invention will be further described for the following example, and the present invention is not limited.
Embodiment one apigenin is to the protective effect of the L929 programmed cell necrosis of death receptor mediation
The trophophase L929 cell of taking the logarithm, 1x10
5/ ml is inoculated in the 6 porocyte culture plates.(1) normal control group is established in experiment; (2) simple tumor necrosis factor (TNF-α) processed group; (3) TNF-α and known inhibitor of cellular necrosis Nec-1 coprocessing group; (4) simple apigenin processed group; (5) add TNF-α processed group after the apigenin pretreatment; (6) simple tripterine (Cel) processed group; (7) add TNF-α processed group after the tripterine pretreatment.Next day (5) (7) group added apigenin and tripterine pretreatment respectively after 6 hours, remove medicine, cell is after the PBS flushing, change fresh culture, except that (1) group, each group adds 100ng/ml tumor necrosis factor (TNF-α) respectively, peptic cell after 24 hours, the blue dyeing of Placenta Hominis, the living cell counting number, and calculate the cells survival percentage rate.The result as shown in Figure 4, the apigenin pretreatment shows the downright bad protective effect of good cell, can obviously reduce the alpha mediated cell death of TNF-after the pretreatment, its protective effect and Nec-1 are suitable.
Embodiment two apigenins are to the protective effect of SD (Sprague-Dawley) rat cerebral ischemia reperfusion injury
Healthy male SD rat, body weight 300-350 gram is divided into 4 groups at random: sham operated rats, model group (ligation cause cerebral ischemia after 2 hours perfusion 24 hours again), nimodipine positive controls and apigenin treatment group.First three sky of art, nimodipine group and apigenin treatment treated animal are respectively at lumbar injection 1mg/kg/day nimodipine or 20mg/kg/day apigenin.Adopt the method for Longa to prepare SD cerebral ischemic reperfusion in rats model after three days, each group press the 3mg/kg nimodipine or 3mg/kg apigenin dosage is distinguished intravenous administration once at ischemia after 1 hour, ischemia perfusion 24 hours again after 2 hours.Each treated animal sacrificed by decapitation is got cerebral tissue and is prepared crown brain sheet, and 2,3, the dyeing of 5-triphenyl tetrazolium chloride (TTC) method is observed and is measured the infarct volume.
Table 1. tripterine is to the influence of rat cerebral ischemia reperfusion injury cerebral infarct volume
Compare * P＜0.05 with model group; * P＜0.01; Compare #P＜0.05 with the nimodipine group
As can be seen from Table 1, compare with model group, known positive drug nimodipine can effectively reduce the volume by ischemic reperfusion damage causing cerebral infarction, and apigenin has significant protective effect equally, and effect is better than nimodipine.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910084958A CN101711758A (en) | 2009-06-05 | 2009-06-05 | Application of apigenin in preparing medicament for preventing and treating diseases caused by ischemic injuries of humans |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910084958A CN101711758A (en) | 2009-06-05 | 2009-06-05 | Application of apigenin in preparing medicament for preventing and treating diseases caused by ischemic injuries of humans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101711758A true CN101711758A (en) | 2010-05-26 |
Family
ID=42416008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910084958A Pending CN101711758A (en) | 2009-06-05 | 2009-06-05 | Application of apigenin in preparing medicament for preventing and treating diseases caused by ischemic injuries of humans |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101711758A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523736A (en) * | 2015-01-06 | 2015-04-22 | 李子林 | Pharmaceutical composition for myocardial infarction prevention and treatment and application thereof |
| CN107823197A (en) * | 2017-11-01 | 2018-03-23 | 中国医学科学院阜外医院 | Application of the apiolin in hemorrhagic cerebrovascular disease and ICVD medicine caused by prevention and treatment hypertension is prepared |
| CN109568584A (en) * | 2018-12-06 | 2019-04-05 | 上海交通大学医学院 | BRAF inhibitor is used to prepare the newtype drug and its screening technique for the treatment of procedure necrosis disease |
| CN111557326A (en) * | 2020-05-20 | 2020-08-21 | 南昌大学 | Butter crisp biscuit and preparation method thereof |
-
2009
- 2009-06-05 CN CN200910084958A patent/CN101711758A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523736A (en) * | 2015-01-06 | 2015-04-22 | 李子林 | Pharmaceutical composition for myocardial infarction prevention and treatment and application thereof |
| CN104523736B (en) * | 2015-01-06 | 2018-03-16 | 李子林 | A kind of pharmaceutical composition for preventing and treating myocardial infarction and its application |
| CN107823197A (en) * | 2017-11-01 | 2018-03-23 | 中国医学科学院阜外医院 | Application of the apiolin in hemorrhagic cerebrovascular disease and ICVD medicine caused by prevention and treatment hypertension is prepared |
| CN109568584A (en) * | 2018-12-06 | 2019-04-05 | 上海交通大学医学院 | BRAF inhibitor is used to prepare the newtype drug and its screening technique for the treatment of procedure necrosis disease |
| CN111557326A (en) * | 2020-05-20 | 2020-08-21 | 南昌大学 | Butter crisp biscuit and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101715274B1 (en) | Composition containing extract or fractions of Chrysanthemum indicum L. for treating, improving or preventing inflammatory disease | |
| Mikaeili et al. | Antifungal activities of Astragalus verus Olivier. against Trichophyton verrucosum on in vitro and in vivo guinea pig model of dermatophytosis | |
| JP2008519767A (en) | Herbal composition PHY906 and its use in chemotherapy | |
| CN101711758A (en) | Application of apigenin in preparing medicament for preventing and treating diseases caused by ischemic injuries of humans | |
| CN107496573B (en) | Application of Houttuynia cordata extract in the preparation of pharmaceutical preparations for preventing myocardial ischemia-reperfusion injury | |
| CN108605931B (en) | Application of Four Compounds in Preparation of Nematicidal Drugs | |
| JP4371431B2 (en) | Antiallergic composition | |
| Emmanuel et al. | Covid 19: resveratrol as a potential supplement to mitigate the cardiotoxicity associated with chloroquine and hydroxychloroquine treatment | |
| CN102631525A (en) | Health care product with function of blood pressure reduction and preparation method thereof | |
| JP2020121959A (en) | Pharmaceutical composition and autophagy cell death inducer | |
| TWI469784B (en) | Therapeutic compositoin for treating cancers | |
| JP5872769B2 (en) | Graft rejection inhibitory composition containing Cordyceps mycelium extract as an active ingredient | |
| CN101199534B (en) | Anti-tumor function of raw panoxadiol derivative | |
| CN106606603A (en) | Dark tea extract, and applications of food-drug composition taking dark tea extract as main ingredient in radiation prevention | |
| CN111632146B (en) | Application of OAT inhibitor and oncolytic virus in preparation of antitumor drugs | |
| JP2002510640A (en) | Herbal composition for prevention and treatment of AIDS | |
| CN102210725B (en) | Application of hypericum japonicum thunb general flavone in preparing medicament for treating hepatic fibrosis | |
| KR101785096B1 (en) | Composition for Treatment of Brain cancer and Functional Whitening cosmetic Comprising Extract of TRIGONELLAE SEMEN | |
| CN110507651B (en) | Medicine with non-small cell lung cancer resisting effect and application thereof | |
| EP3013330B1 (en) | Anti-viral compound and composition | |
| de Sousa Medeiros et al. | Antifungal activity of isoeugenol and its interaction with nystatin against Candida tropicalis and Candida glabrata mouth isolates: an in vitro study | |
| JP2005289942A (en) | Peripheral circulation improver preparation | |
| KR20230115235A (en) | Pharmaceutical composition for alleviating inflammation containing Syzygium aromaticum L. and Sorbus commixta Hedl. complex extracts | |
| KR20230089631A (en) | Composition of herbal medicine mixture with the enhanced immune activity | |
| CN106581027B (en) | Compound and pharmaceutical application, composition and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100526 |